Executive Summary

Canada's private pharmaceutical market is a big and growing opportunity for companies, but taking a piece of the pie is not as easy as it used to be, says Arvind Mani, director of market access and policy research at PDCI Market Access (PDCI), a Canadian pricing and reimbursement consultancy. Private insurers are starting to worry about cost containment and according to PDCI, product listing agreements could become a prerequisite for companies selling expensive specialty drugs. In an interview with Scrip, Mani explained what companies need to know about these agreements to get ahead.